close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sana Biotechnology, Inc

< Previous 1 2 Next >
Sana Biotechnology Announces Pricing of Upsized Public Offering
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Proposed Public Offering of Common Stock
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at November and December 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at September 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at June 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at May 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Host Research & Development Day
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
Tickers SANA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today